First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Leuk Lymphoma. 2012 Aug;53(8):1494-500. doi: 10.3109/10428194.2012.660627. Epub 2012 Mar 1.
Since the introduction of rituximab (R), the prognosis for diffuse large B-cell lymphoma (DLBCL) has markedly improved. We evaluated the prognostic significance of serum soluble CD27 (sCD27) in 143 patients with DLBCL treated with cyclophosphamide, doxorubicin, vincristine and prednisolone plus rituximab (R-CHOP). Five-year overall survival rates for patients with sCD27≥213 U/mL or <213 U/mL were 38.7% and 76.8%, respectively (p =0.0005). Multivariate analysis revealed that serum sCD27 was significantly correlated with OS (p =0.047). Immunohistochemical staining for CD27 in lymphoma tissues revealed positive lymphoma cells in 22 cases (18.5%) and positive microenvironment T-cells in 62 cases (52.1%) and was negative in the remaining patients. In these three subgroups, median sCD27 levels were 336 U/mL, 242.6 U/mL and 109.9 U/mL, respectively (p =0.004). Thus, serum sCD27 level is associated with CD27 expression on lymphoma cells, and may be a powerful prognostic factor for DLBCL.
自从利妥昔单抗（R）问世以来，弥漫性大 B 细胞淋巴瘤（DLBCL）的预后有了显著改善。我们评估了血清可溶性 CD27（sCD27）在 143 例接受环磷酰胺、多柔比星、长春新碱和泼尼松联合利妥昔单抗（R-CHOP）治疗的 DLBCL 患者中的预后意义。sCD27≥213 U/mL 或 <213 U/mL 的患者 5 年总生存率分别为 38.7%和 76.8%（p=0.0005）。多变量分析显示血清 sCD27 与 OS 显著相关（p=0.047）。淋巴瘤组织中 CD27 的免疫组织化学染色显示 22 例（18.5%）阳性淋巴瘤细胞和 62 例（52.1%）阳性微环境 T 细胞，其余患者均为阴性。在这三个亚组中，sCD27 水平的中位数分别为 336 U/mL、242.6 U/mL 和 109.9 U/mL（p=0.004）。因此，血清 sCD27 水平与淋巴瘤细胞上的 CD27 表达相关，可能是 DLBCL 的一个有力预后因素。
